Agnes Maj-Hes

Agnes Maj-Hes
Wiener Krankenanstaltenverbund · Department of Pulmology

Doctor of Medicine
Oncology at the Pulmology Department Otto Wagner Spital

About

25
Publications
1,548
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
210
Citations

Publications

Publications (25)
Article
Enzalutamide (ENZA) is a frequently used therapy in metastatic castration‐resistant prostate cancer (mCRPC). Baseline or acquired resistance to ENZA have been observed, but the molecular mechanisms of resistance are poorly understood. We aimed to identify proteins involved in ENZA resistance and to find therapy‐predictive serum markers. We performe...
Article
Full-text available
In this analysis, we examined the efficacy, feasibility, and limitations of the application of mTOR inhibitors based on the individual molecular profiles of pretreated cancer patients after the failure of all standard treatments in the palliative setting. In this single-center, real-world analysis of our platform for precision medicine, we analyzed...
Article
Full-text available
IntroductionThis study aimed to assess the effects of multiple docetaxel (DOC) treatments on prostate-specific antigen (PSA) kinetics and survival among patients with metastatic castration-resistant prostate cancer (mCRPC) who were sensitive to first-line DOC and received no other life-prolonging agents. To eliminate the effect of cortisone on seru...
Article
Objectives The rapidly changing treatment landscape in metastatic castration-resistant prostate cancer (mCRPC) calls for biomarkers to guide treatment decisions. We recently identified MMP-7 as a potential serum marker for the prediction of response and survival in mCRPC patients who received docetaxel (DOC) chemotherapy. Here, we aimed to test thi...
Article
Objectives: To assess chromogranin A (CGA) and neuron-specific enolase (NSE) levels as well as their changes in different stages of prostatic adenocarcinomas (PCA). Methods: Overall, 1095 serum samples of 395 patients divided in three treatment groups were analysed; the radical prostatectomy (RPE) cohort (n=157) included patients with clinically...
Article
Background: To assess which parameters of [68 Ga]Ga-PSMA-11 positron emission tomography (PSMA-PET) predict response to systemic therapies in metastatic (m) castration-resistant prostate cancer (CRPC). In addition, to investigate which of these factors are associated with overall survival (OS). Methods: We retrospectively assessed the following...
Article
Full-text available
Introduction Determination of circulating prostate specific antigen (PSA) is commonly used in the diagnosis and treatment monitoring of prostate cancer [1]. Presently, PSA testing is performed in centralized laboratories, which is associated with prolonged time between venipuncture and the PSA value being available. In this prospective study, we pr...
Article
Introduction: High baseline YKL-40 serum levels are associated with drug resistance in several solid tumours. However, their role in predicting docetaxel (DOC) resistance in prostate cancer (PCa) is unknown. Methods: Pre-treatment serum levels of YKL-40 and prostate-specific antigen (PSA) were analyzed in 109 castration-resistant prostate cancer...
Article
Aim: To assess the ability of apparent diffusion coefficient (ADC) measurements obtained by MRI to predict disease-specific survival (DSS) in patients with bladder cancer and compare it with established clinico-pathological prognostic factors. Material and methods: The ethical review board approved this cross-sectional study. Patients with suspe...
Article
Full-text available
Purpose To assess the predictive value of pre‐chemotherapy MMP‐7, sFas, FasL serum levels as well as their changes during therapy. Patients and Methods Serum levels of MMP‐7, Fas and FasL were determined by ELISA in 96 CRPC patients; 21 docetaxel‐resistant who received one single series and 75 docetaxel‐sensitive who received repeated series of do...
Article
Background: There are no clear data regarding the association between body mass index (BMI) and outcomes after radical prostatectomy (RP). This study aimed to investigate the association between BMI and biochemical recurrence (BCR) after RP in a large international contemporary cohort of patients with prostate cancer. Methods: We retrospectively...
Article
Background: The neutrophil-to-lymphocyte ratio (NLR) as a marker of systemic inflammatory response has been proposed as a prognostic factor for patients with urothelial carcinoma of the bladder (UCB) following radical cystectomy (RC). Objective: To validate NLR as a prognostic biomarker and to perform a pooled meta-analysis. Design, setting, an...
Article
Purpose of review We review recent data on immunotherapies for bladder cancer and discuss strategies to maximize the antitumor effect of immunotherapy in solid tumors. Recent findings Anti-programmed death ligand 1 has shown promise in advanced bladder cancer. Clinical trials of immune checkpoint inhibitors as monotherapy or in combination are unde...
Article
Aim: In castration- and docetaxel-resistant prostate cancer cells, sorafenib has been shown to cause apoptosis through downregulation of myeloid cell leukemia-1, phosphorylation of Akt and inhibition of androgen receptor (AR) expression as well as of its constitutively active, C-terminally truncated AR lacking the AR-ligand binding domain. We aimed...
Article
Clinical management of prostate cancer (PC) is still highly demanding on the identification of robust biomarkers which will allow a more precise prediction of disease progression. We profiled both mRNA expression and DNA copy number alterations (CNAs) from laser capture microdissected cells from 31 PC patients and 17 patients with benign prostatic...
Article
Objective: To determine if mammalian target of rapamycin (mTOR) inhibitor (everolimus or temsirolimus) rechallenge in the third- or fourth-line setting after sequential use of a vascular endothelial growth factor receptor (VEGF)-targeted agent and an mTOR inhibitor is a feasible and effective treatment strategy in patients with metastatic renal ce...
Article
Full-text available
Telomere dysfunction is an early event in the development of prostate cancer and telomerase (TERT) activity is detectable in the majority of prostate cancers. Genetic variation in TERT and its regulatory elements may influence prostate carcinogenesis. MNS16A, a functional polymorphic tandem repeat minisatellite of TERT, has been studied in several...
Article
375 Background: The question regarding the benefit of a TKI rechallenge versus switch to an mTOR inhibitor (mTORi) in mRCC pts who responded to a previous line of TKI remains unanswered and is a common dilemma in clinical practice. We report results of a retrospective study to address this question. Methods: This study retrospectively investigated...
Article
442 Background: question regarding the benefit of a mTORi re-challenge for pts treated with a previous line of TKI and 1 line of mTORi remains unanswered in mRCC. Methods: this study retrospectively investigated Treatment Duration (TD), best overall response (OR) in pts treated with TKI and mTORi in a sequence temsirolimus-everolimus (T-E) or evero...
Article
AURKA is a centrosome-associated serine/threonine kinase involved in mitotic chromosomal segregation. The AURKA gene is located on chromosome 20q13, also known as HPC20 prostate cancer susceptibility locus. Therefore, we investigated in this Caucasian case-control study two single nucleotide polymorphisms (SNPs) of the AURKA gene, rs8173 located in...

Network

Cited By

Projects

Projects (3)
Archived project
Archived project
Archived project